← Back to screener

Oruka Therapeutics, Inc. ORKA

Rank #2515 · Nasdaq · $5.8B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
9.3
P/E
-55.4
P/B
5842433.22
ROE
-10543300.0%
Op. Margin
–%
Debt Ratio
1379800%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -55.4x, P/B 5842433.22x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -10543300.0%. Ranks in the top 100% of the universe.

Safety ★☆☆☆☆
Poor

Debt ratio 1379800%. Ranks in the top 100% of the universe. Above 200% signals meaningful leverage risk.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Valuation is the relative strength (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$-0.0B–-1204
2012–$-0.0B$-0.0B$-0.0B–-670
2013–$-0.0B$-0.0B$-0.0B–-265
2014$0.0B$-0.0B$-0.0B$0.0B–52
2015$0.0B$-0.0B$-0.0B$0.0B–9
2016$0.0B$-0.0B$-0.0B$0.0B–10
2017$0.0B$-0.0B$-0.0B$0.0B–6
2018$0.0B$-0.0B$-0.0B$0.0B–9
2019$0.0B$-0.0B$-0.0B$0.0B–-34
2020$0.0B$-0.0B$-0.0B$0.0B–15
2021$0.0B$-0.0B$-0.0B$0.0B–51
2022$0.0B$-0.0B$-0.0B$0.0B–8
2023$0.0B$-0.0B$-0.0B$0.1B–3
2024–––$0.0B–1379800
2025–$-0.1B$-0.1B$0.0B–1379800

← See the full screener